JHU

ORYZON Announces U.S. FDA Clearance of CTEP-CRADA Phase I/II Clinical Trial Sponsored by NCI for Iadademstat Plus Immune Checkpoint Inhibitors in 1L Extensive Stage Small Cell Lung Cancer

Retrieved on: 
Monday, April 8, 2024
JHU, NCI, Development, Carcinoma, CRADA, National Cancer Institute, MSKCC, IND, Investigational New Drug, Genomics, Immune system, Bangladesh Technical Education Board, FDA, SCLC, Food, Pharmaceutical industry

This will be the first clinical trial testing the combination of iadademstat with immune checkpoint inhibitors.

Key Points: 
  • This will be the first clinical trial testing the combination of iadademstat with immune checkpoint inhibitors.
  • The trial ( NCT06287775 ) is entitled “A Phase I Dose Finding and Phase II Randomized Trial of Iadademstat Combined With Immune Checkpoint Inhibition Maintenance After Initial Chemoimmunotherapy in Patients With Extensive-Stage Small Cell Lung Cancer”.
  • “We are very pleased that NCI has received the regulatory approval from the FDA to initiate this first-in-human Phase I/II combination trial with iadademstat plus immune check point inhibitors” stated Dr. Carlos Buesa, Chief Executive Officer of Oryzon.
  • “The molecular mechanisms underlying the ability of iadademstat to render small cell lung cancer cells visible to the immune system while simultaneously enhancing immune activity to aggressively target these malignant cells have been clearly elucidated.

Immuron Clinical Trials Update

Retrieved on: 
Friday, December 22, 2023
Spore, Clostridioides difficile, ASX, Immuron, Principal, Diarrhea, FDA, NMRC, Campylobacter, IMC, Johns Hopkins University, Trial of the century, MD, Agriculture, Clinical trial, GLP, Volunteering, Escherichia, Escherichia coli, CIR, CHIM, Patient, Monash University, Safety, JHU, Clostridioides, Pharmaceutical industry

MELBOURNE, Australia, Dec. 22, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to provide shareholders and the market with an update on the company’s clinical development portfolio.

Key Points: 
  • The NMRC has recently completed the in-patient stage of the campylobacter challenge clinical study.
  • Headline results from the clinical trial are anticipated to be reported in H2 2024.
  • The Phase 2 clinical trial is designed to evaluate the safety and protective efficacy of the new product manufactured by Immuron compared to a placebo in a controlled human infection model (CHIM).
  • The inpatient challenge phase of the Travelan clinical study led by Principal Investigator Dr Mohamed Al-Ibrahim at the Pharmaron CPC FDA inspected Clinical Research Facility Inpatient Unit located in Baltimore, Maryland US, has been completed.

The Foundation for Sarcoidosis Research (FSR) awards $100,000 in support of cardiac sarcoidosis

Retrieved on: 
Monday, December 18, 2023
School, Faculty, Duke University Hospital, Partnership, Prognosis, Research, Pathology, Inflammation, Disease, Johns Hopkins University, Doctor of Philosophy, Sarcoidosis, Transplant, Duke University, University, 3D, University of Pennsylvania, Assistant, Diagnosis, Public health, JHU, FSR, Medical device

CHICAGO, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Foundation for Sarcoidosis Research (FSR) announces $100,000 in funding for support of research aimed at improving diagnosis, management, and treatment of cardiac sarcoidosis.

Key Points: 
  • CHICAGO, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Foundation for Sarcoidosis Research (FSR) announces $100,000 in funding for support of research aimed at improving diagnosis, management, and treatment of cardiac sarcoidosis.
  • With this grant, we aim to improve the specificity of cardiac sarcoidosis diagnosis with FDG-PET using a novel strategy incorporating combined SGLT1/2 inhibition with sotagliflozin.
  • “The 2023 FSR Sarcoidosis Cardiac Grant award will allow us to use the novel 3D multi-omic pathology to determine unique properties of vasculature surrounding cardiac sarcoidosis granulomas and find new potential biomarker targets and histological criteria for cardiac sarcoidosis diagnosis.
  • FSR is dedicated to accelerating sarcoidosis research through fellowships, small grants, large grants, and disease specific grants to advance sarcoidosis research and advance care for those living with sarcoidosis.

Immuron Announces First Patients Enrolled in Campylobacter Challenge Clinical Study

Retrieved on: 
Monday, December 4, 2023
ASX, Immuron, Principal, IBS, Diarrhea, NMRC, ETEC, Campylobacter, Disease, IMC, Trial of the century, Johns Hopkins University, MD, Clinical trial, Enterotoxigenic Escherichia coli, Infection, Morale, CIR, CHIM, Gastroenteritis, Safety, JHU, Judgement, Pharmaceutical industry

MELBOURNE, Australia, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce that the US Naval Medical Research Command (NMRC) has initiated the clinical evaluation of a new oral therapeutic targeting Campylobacter and Enterotoxigenic Escherichia coli (ETEC) developed in collaboration with Immuron. The NMRC has prioritized the clinical development of the study to evaluate the efficacy of the new therapeutic product to prevent infectious diarrhea caused by Campylobacter.

Key Points: 
  • The NMRC has prioritized the clinical development of the study to evaluate the efficacy of the new therapeutic product to prevent infectious diarrhea caused by Campylobacter.
  • The clinical study is being led by Principal Investigator Dr Kawsar Talaat, MD at the Johns Hopkins University (JHU) Center for Immunization Research (CIR) Inpatient Unit, located at the JHU Bayview Medical Campus, Baltimore, Maryland.
  • The dosing, challenge and the in-patient stage of the study is anticipated to be completed by the third week of December 2023.
  • The estimated study completion date (last participant, last visit) is June 2024 with headline results from the clinical trial expected to be reported in 2H 2024.

Inhibitor Therapeutics, Inc. Exclusive License with Johns Hopkins University

Retrieved on: 
Wednesday, December 13, 2023
Licensing factor, Johns Hopkins University, FGF, HUVEC, Inhibitor, JHU, Itraconazole, Basal-cell carcinoma, Therapy, National Cancer Institute, VDAC1, INTI, Literature, Cell proliferation, Patient, BCC, EGF, Angiogenesis inhibitor, Prostate cancer, Endothelium, AMPK, VEGF, Neoplasm, System, License, Blood, Enzyme inhibitor, Cancer, ATP, Lung cancer, Growth, API, Metastasis, Invention, RNA, Patent, Pharmaceutical industry, Vaccine

TAMPA, Fla., Dec. 13, 2023 /PRNewswire/ -- Inhibitor Therapeutics, Inc. ("Inhibitor") (OTCQB: INTI) has entered into an exclusive, worldwide licensing agreement (the "License") with Johns Hopkins University (JHU) for their U.S Patent 8,980,930 (Canada Patent 2,572,223) "New Angiogenesis Inhibitors". Angiogenesis Inhibitors, as described by the National Cancer Institute, are unique cancer fighting agents as they block the growth of blood vessels that support tumor growth rather than blocking the growth of the tumor cells themselves. Inventors affiliated with JHU developed this patent, listing Itraconazole as an Active Pharmaceutical Ingredient (API) that has anti-angiogenic properties.

Key Points: 
  • TAMPA, Fla., Dec. 13, 2023 /PRNewswire/ -- Inhibitor Therapeutics, Inc. ("Inhibitor") (OTCQB: INTI) has entered into an exclusive, worldwide licensing agreement (the "License") with Johns Hopkins University (JHU) for their U.S Patent 8,980,930 (Canada Patent 2,572,223) "New Angiogenesis Inhibitors".
  • Inventors affiliated with JHU developed this patent, listing Itraconazole as an Active Pharmaceutical Ingredient (API) that has anti-angiogenic properties.
  • Inhibitor believes the License is a mutually beneficial agreement, yielding a modest annual royalty rate with milestone payments typical to such a license.
  • A total of 13 new 'surgically eligible' lesions across 8 of the 38 patients developed over the duration of the study.

SENIOR ACADEMIC PHILANTHROPY LEADER KIM M. MORTON, JD, MA, NAMED NEW ASSOCIATE DEAN FOR DEVELOPMENT AT UNIVERSITY OF MARYLAND MEDICINE

Retrieved on: 
Tuesday, November 28, 2023
Johns Hopkins University, School, JD, Associate, JHU, Research, The, Senior, Hope, Maryland School, Dean (education), UMMC, Student, Patient, Faculty, Culture, UMM, Trust, War Doctor, Wellesley College, Friends, Wilmer Ophthalmological Institute, University, Development, Bryn Mawr School, Education, George Washington University, Catholic higher education, Volunteering, Health, Hospital, CUA, Bachelor of Arts, Management, Boston, MD, Neurology

BALTIMORE, Nov. 28, 2023 /PRNewswire/ -- University of Maryland School of Medicine (UMSOM) Dean Mark T. Gladwin, MD, along with University of Maryland Medical Center (UMMC) President and CEO, Bert W. O'Malley, MD, announced today that Kim M. Morton, JD, MA, who has led advancement operations for major academic and healthcare institutions during her career, will become Associate Dean for Development at University of Maryland Medicine Philanthropy, the joint advancement operation of the UMSOM and UMMC. Ms. Morton, who was selected as the top candidate, following a national search, will report to Heather Culp, Senior Vice President, Chief Philanthropy Officer and Senior Associate Dean. Her appointment will begin December 18.

Key Points: 
  • Ms. Morton, who was selected as the top candidate, following a national search, will report to Heather Culp, Senior Vice President, Chief Philanthropy Officer and Senior Associate Dean.
  • The appointment of Ms. Morton follows the recent alignment of the UMSOM and UMMC Development Offices under the leadership of Ms. Culp as Chief Philanthropy Officer for the combined entity, University of Maryland Medicine Philanthropy.
  • "It is a particularly exciting and dynamic time right now at the University of Maryland Medicine," said Dean Gladwin.
  • "I am excited to partner with Heather Culp, Dean Gladwin, Dr. O'Malley, and the talented team at University of Maryland Medicine Philanthropy," Ms. Morton said.

Johns Hopkins University Press and NSTA Collaborate to Bring New Instructional Materials to Educators Nationwide

Retrieved on: 
Wednesday, October 11, 2023
University, Primary, Secondary, Education, Other Health, Health, Other Science, Training, Research, Science, Other Education, Continuing, Partnership, Multimedia, Knowledge, Science education, JHU, Student, Johns Hopkins University Press, Book, Planet, JHUP, Fungus, Laboratory, NSTA, Artificial intelligence, Collection, Doctor of Philosophy, Johns Hopkins, National Science Teaching Association, Learning, Problem solving, Conference, Johns Hopkins University, Tutoring, Management, STEM

Johns Hopkins University Press (JHUP) and the National Science Teaching Association (NSTA) have joined together to bring new, free, classroom-ready lesson plans to middle school and high school science and STEM teachers nationwide.

Key Points: 
  • Johns Hopkins University Press (JHUP) and the National Science Teaching Association (NSTA) have joined together to bring new, free, classroom-ready lesson plans to middle school and high school science and STEM teachers nationwide.
  • View the full release here: https://www.businesswire.com/news/home/20231011246657/en/
    Launched today, the Johns Hopkins Wavelengths: Tuning In to Cutting-edge Sciences lesson plans will connect the pioneering discoveries and solutions of Johns Hopkins researcher-professors to classrooms across the country.
  • “We’re thrilled that the groundbreaking work of eminent researchers at Johns Hopkins University has been transformed into these evidence-based, illuminating lesson plans for educators and their students.
  • Later this month, the newest Johns Hopkins Wavelengths lesson plan, Why are most auroras observed near the North and South Poles?

Clearmind Medicine Announces Clinical Research Collaboration with Johns Hopkins University to Evaluate CMND-100 in Patients with Alcohol Use Disorder

Retrieved on: 
Wednesday, September 6, 2023
CSE, Therapy, Johns Hopkins School of Medicine, Clinical trial, MEAI, FSE, Doctor of Philosophy, Associate, JHU, Crave, AUD, Patient, CWY, Pharmacology, Psychiatry, Behavioural sciences, Johns Hopkins, Safety, Pharmaceutical industry, Medicine

"We are honored to collaborate with JHU for our first in human clinical trial.

Key Points: 
  • "We are honored to collaborate with JHU for our first in human clinical trial.
  • "Johns Hopkins is our second US clinical site joining our trial, following Yale School of Medicine’s Department of Psychiatry.
  • The patients will report their drinking patterns and craving for alcohol (and cigarettes) during the clinical trial period.
  • CM-CMND-001 clinical trial is a multinational, multi-center, Phase I/II single- and multiple-dose tolerability, safety and pharmacokinetic study in healthy volunteers and AUD subjects.

DATA BREACH ALERT: Edelson Lechtzin LLP Is Investigating Claims On Behalf Of Customers Whose Personal Data May Have Been Compromised By Johns Hopkins University and Health System Data Breach

Retrieved on: 
Thursday, June 22, 2023
LLP, JHU, Name, Social, Patient, Social Security, HERE, Privacy, Private investigator, D.C

NEWTOWN, Pa., June 22, 2023 (GLOBE NEWSWIRE) -- The law firm of Edelson Lechtzin LLP is investigating claims regarding data privacy violations by Johns Hopkins University and Health System (“JHU”).

Key Points: 
  • NEWTOWN, Pa., June 22, 2023 (GLOBE NEWSWIRE) -- The law firm of Edelson Lechtzin LLP is investigating claims regarding data privacy violations by Johns Hopkins University and Health System (“JHU”).
  • JHU learned of suspicious activity on or about May 31, 2023, and notified customers on or about June 14, 2023.
  • How can I protect my personal data?
  • Edelson Lechtzin LLP is investigating bringing a class action lawsuit to seek legal remedies on behalf of customers who may have had their sensitive personal and patient data compromised by the JHU data breach.

Immuron Announces FDA Removed Clinical Hold on New Campylobacter ETEC Therapeutic Paves way for Clinical Trial Initiation

Retrieved on: 
Monday, May 8, 2023
Volunteering, Institutional review board, Immuron, IMC, US Foods, Campylobacteriosis, Infection, Irritable bowel syndrome, US military watches, Campylobacter, CIR, ETEC, ASX, Enterotoxigenic Escherichia coli, Diarrhea, Judgement, Trial of the century, JHU, Investigational New Drug, Johns Hopkins University, Naval Medical Research Center, Gastroenteritis, Disease, NMRC, Johns, Ethics, Ageing, National Institute of Cholera and Enteric Diseases, FDA, Morale, IND, Food, Safety, Pharmaceutical industry, Vaccine

MELBOURNE, Australia, May 08, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, is pleased to announce that the US Naval Medical Research Center (NMRC) has received approval from the US Food and Drug Administration (FDA) to proceed with the clinical evaluation of a new oral therapeutic targeting Campylobacter and Enterotoxigenic Escherichia coli (ETEC) developed in collaboration with Immuron. The FDA has removed a clinical hold on the Investigational New Drug (IND) application allowing the NMRC to proceed with its plans to evaluate the efficacy of the hyperimmune product to prevent infectious diarrhoea caused by Campylobacter and ETEC which is now active.

Key Points: 
  • The FDA has removed a clinical hold on the Investigational New Drug (IND) application allowing the NMRC to proceed with its plans to evaluate the efficacy of the hyperimmune product to prevent infectious diarrhoea caused by Campylobacter and ETEC which is now active.
  • The first clinical study will be conducted at the Johns Hopkins University (JHU) Center for Immunization Research (CIR) Inpatient Unit, located at the Johns Hopkins Bayview Medical Campus.
  • Infectious diarrhoea is the most common illness reported by travellers visiting developing countries and among US troops deployed overseas.
  • This release has been authorised by the directors of Immuron Limited.